GEN News Highlights

New Sponge-Based Therapeutic Cancer Vaccine Begins Human Clinicals

(Page
1
of
1)

A research group reports that they started a Phase I clinical trial of an implantable vaccine to treat melanoma. The vaccine is novel because it uses a small disk-like sponge about the size of a fingernail that is made from FDA-approved polymers. Current therapeutic cancer vaccines require doctors to first remove the patient’s immune cells from the body, reprogram them, and then reintroduce them back into the body, a more time-consuming and complex process.

The work represents a collaborative effort being pursued at the Wyss Institute for Biologically Inspired Engineering at Harvard University. It was led by Wyss Institute core faculty member David J. Mooney, Ph.D., who is also the Robert P. Pinkas Family professor of Bioengineering at the Harvard School of Engineering and Applied Sciences, and Wyss Institute associate faculty member Glenn Dranoff, M.D., who is co-leader of Dana-Farber Cancer Institute’s Cancer Vaccine Center.

The new approach was first reported to eliminate tumors in mice four years ago. The sponge, which is implanted under the skin, is designed to recruit and reprogram a patient’s own immune cells on site, instructing them to travel through the body, home in on cancer cells, and then kill them.

“We addressed the hypothesis that coordinated regulation of a DC [dendritic cell] network, and plasmacytoid DCs (pDCs) and CD8+ DCs in particular, could enhance host immunity in mice,” wrote the researchers in an article (“In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice”) in Science Translational Medicine (November 25, 2009). “We used functionalized biomaterials incorporating various combinations of an inflammatory cytokine, immune danger signal, and tumor lysates to control the activation and localization of host DC populations in situ.”

In that 2009 study, 50 percent of mice treated with two doses of the vaccine—mice that would have otherwise died from melanoma within about 25 days—showed complete tumor regression. The technology was initially designed to target cancerous melanoma in skin, but the scientists believe it might have application to other cancers and inflammatory diseases.

“It is rare to get a new technology tested in the laboratory and moved into human clinical trials so quickly,” said Dr. Dranoff. “We’re beyond thrilled with the momentum, and excited about its potential.”

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

Be sure to take the GEN Poll

Climate Change

How would you describe the researchers response to the 2°C global temperature target?

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

38.9%

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

22.2%

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.